Business & Industry
Insilico and Servier Join Hands for New Oncology Therapies
Insilico Medicine has gone ahead with a multi-year research and development - R&D collaboration with Servier, of almost $888m, in order to develop and discover certain new oncology therapies. The partnership combines the AI drug discovery platforms of Insilico...
Business & Industry
J&J Acquires Clinical-Stage Biotechnology Firm for $3.05bn
Johnson & Johnson - J&J has completed theย acquisition of Halda Therapeutics which is a clinical-stage biotechnology firm for an amount of $3.05bn in cash.
This move goes on to bring the Regulated Induced Proximity Targeting Chimera -RIPTAC platform from Haldaย to...
News
Celltrion Eyes Full-Scale Contract Manufacturing Operations
Celltrion on January 02, 2026, announced that it has completed the transfer of the biopharmaceutical production facility of Eli Lilly thatโs located in Branchburg, New Jersey, and is now entering full-scale contract manufacturing operations - CMO when it comes...
Business & Industry
CMS Unveils a New Voluntary Access Programme For GLP-1
In the most recent of a stringย of announcements ahead of the holiday season, Centers for Medicare & Medicaid Services (CMS) has unveiled a new voluntary access programme which aims to widen the usage of GLP-1 agonist medicines when it...
Business & Industry
Bevacizumab to be Used by NHS for Colorectal Cancer
NICE has gone ahead and cleared the way for bevacizumab to be used by NHS in order to treat colorectal cancer for the very first time, all thanks to the availability when it comes to the lower-cost biosimilar versions...
Business & Industry
Sanofi to Buy Vaccine Developer Dynavax in a $2.5b Deal
The French pharma giant, Sanofi, has started a $15.50 per share cash tender offer when it comes to Emeryville, California-based vaccine developer Dynavax, which already goes on to market an adult vaccine that protects against the hepatitis B virus...
BioPharma
AstraZeneca Commits $100mn for Pan-KRAS Inhibitor by Jacobio
AstraZeneca has gone ahead and committed $100 million to head deeper into the KRAS space by way of securing the right when it comes to a clinical-stage, multitarget asset from Jacobio Pharma of China.
The U.K.-based pharma giant has scored...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read
















